Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

SANOFI - PRODUTOS FARMACÊUTICOS, LDA

NIF 500134960
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €74,895,728 138 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €74,895,728 138 contracts
A2 · Late Publication €17,905,217,535 5,600 contracts
Contract published to BASE more than 10 days after the signing date
LOW €17,905,217,535 5,600 contracts
A5 · Threshold Splitting €40,507,335 181 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €40,507,335 181 contracts
A6 · Low Competition €507,955,997 167 contracts
Only one bidder participated in a competitive procedure
MEDIUM €507,955,997 167 contracts
A9 · Price Overrun €73,764 7 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €73,764 7 contracts
A9 · Abnormal Price Reduction €23,235,325,304 2,704 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €23,235,325,304 2,704 contracts
C3 · Missing Mandatory Fields €14,326,185 119 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €14,326,185 119 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

335
€1,312,432,947
65
€1,112,172,483
527
€974,909,583
332
€934,480,965
151
€925,670,211
39
€818,516,811
628
€774,629,736
58
€730,416,588
410
€704,702,952
85
€692,263,962
74
€671,905,157
62
€653,576,073
104
€635,987,675
109
€623,649,496
91
€608,544,587
52
€607,357,024
78
€559,213,855
80
€551,428,223
68
€539,506,031
120
€527,792,680
Page 1 of 4 · 78 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 3 · 138 contracts

Medicamento Olipudase alfa 20 mg Pó conc sol inj Fr IV
PT · 13463910 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€1,507,749 2026-02-16
2026/0084-Convite à apresentação de proposta por ajuste direto para aquisição de medicamentos
PT · 12869596 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€251,623 2025-12-17
Medicamento Milrinona 10 mg/10 ml Sol inj Fr 10 ml IV
PT · 11915775 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€16,972 2025-11-10
AQUISIÇÃO URGENTE DE VARIOS MEDICAMENTOS
PT · 11978826 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€68,900 2025-09-30
AQ URGENTE MEDICAMENTOS VÁRIOS
PT · 11944307 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€52,561 2025-08-07
1598/2025-Convite à apresentação de proposta por ajuste direto para aquisição de medicamentos
PT · 11871036 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€3,987,005 2025-07-11
VÁRIOS MEDICAMENTOS
PT · 11525610 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€10,728 2025-05-29
VÁRIOS MEDICAMENTOS
PT · 11472462 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€32,660 2025-05-27
VÁRIOS MEDICAMENTOS
PT · 11425193 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€108,378 2025-05-06
Aquisição Medicamento avalglucosidase alfa 100 mg Pó conc sol inj Fr IV
PT · 11732371 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€391,823 2025-04-22
Aquisição medicamento teriflunomida cp.14mg
PT · 11737496 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€2,659 2025-04-16
MEDICAMENTOS
PT · 11344512 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€47,601 2025-04-11
VÁRIOS MEDICAMENTOS
PT · 11361526 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€66,019 2025-04-07
VÁRIOS MEDICAMENTOS
PT · 11334584 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award
€19,853 2025-04-03
1344/2025-Convite à apresentação de proposta por ajuste direto para aquisição de medicamentos AGREGAÇÃO CENTRALIZADA DE MEDICAMENTOS 2025
PT · 11330198 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A9 · Abnormal Price Reduction
€20,753,076 2025-03-31
VÁRIOS MEDICAMENTOS
PT · 11336893 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€26,845 2025-03-31
VÁRIOS MEDICAMENTOS
PT · 11315143 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€43,093 2025-03-25
1183/2024-CONVITE À APRESENTAÇÃO DE PROPOSTA POR AJUSTE DIRETO PARA AQUISIÇÃO DE CEMIPLIMAB [50 MG/ML; 7 ML; SOL INJ; FRS], DUPILUMAB [200 MG/1.14 ML; SOL INJ; SERINGA], DUPILUMAB [300 MG/ 2 ML; SOL INJ; CANETA/ SERINGA], DUPILUMAB [200 MG/1.14 ML; SOL INJ; CANETA], MILRINONA [10 MG/10 ML; SOL INJ; F/AMP], RASBURICASE [1.5 MG/ML; 5 ML; PÓ CONC SOL INJ; FRS], RASBURICASE [1.5 MG/ML; 1 ML; PÓ CONC SOL INJ; FRS], TIROTROPINA [0,9 MG; F/AMP] E VANDETANIB [100 MG; CÁP/ COMP] PARA SUPRIR NECESSIDADES DAS ENTIDADES DO SNS
PT · 11315915 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A9 · Abnormal Price Reduction
€4,187,344 2025-03-25
VÁRIOS MEDICAMENTOS
PT · 11284920 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€12,379 2025-03-10
Medicamento Olipudase alfa 20 mg Pó conc sol inj Fr IV
PT · 11295828 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€753,874 2025-03-05
Aquisição de vacina contra a poliomielite para as instituições do SNS
PT · 11290448 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€175,401 2025-02-27
Aquisição de Nirsevimab para as instituições do SNS
PT · 11290430 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,023,220 2025-02-27
Aquisição de vacina contra a poliomielite para as instituições do SNS
PT · 11903060 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€175,401 2025-02-26
VÁRIOS MEDICAMENTOS
PT · 11306751 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€43,704 2025-02-24
VÁRIOS MEDICAMENTOS
PT · 11263591 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€76,874 2025-02-19
Aquisição medicamento vandetanib cp. 100mg
PT · 11452818 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€11,416 2025-02-05
Aquisição medicamento avalglucosidase alfa 100 mg Pó conc sol inj Fr
PT · 11448063 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€82,099 2025-01-23
Aquisição medicamento olipudase alfa inj.20mg iv
PT · 11448830 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€335,055 2025-01-23
Aquisição Medicamento etambutol cp. 400mg_medicamento rasburicase 7.5 mg/5 ml pó e conc sol inj fr iv
PT · 11347260 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€11,478 2025-01-08
Aquisição do Medicamento vandetanib cp. 300mg
PT · 11081459 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€7,959 2024-12-11
Aquisição Medicamento cemiplimab inj. 50mg/ml 350mg/7ml iv
PT · 11053161 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€69,902 2024-11-14
Ajuste direto para aquisição de Nirsevimab
PT · 11058222 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€10,019,900 2024-10-10
Ajuste direto para aquisição de Nirsevimab
PT · 11058237 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€10,019,900 2024-10-10
Aquisição de vacina contra a poliomielite para as instituições do SNS
PT · 11060600 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€45,571 2024-09-05
Medicamento rasburicase 7.5 mg/5 ml pó e conc sol inj fr iv
PT · 11004298 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€6,031 2024-09-02
Ajuste direto para aquisição de Nirsevimab
PT · 10965741 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€10,019,900 2024-08-22
Medicamento Pirazinamida cp. 500mg
PT · 11023519 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€12,035 2024-06-28
Medicamento Etambutol cp. 400mg
PT · 11011375 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,085 2024-06-26
Medicamento dupilumab caneta 300mg/2ml sc
PT · 11346354 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields
€335,838 2024-06-13
Medicamento Olipudase Alfa Inj 20 Mg - A.E.
PT · 11024239 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€670,110 2024-05-16
VÁRIOS MEDICAMENTOS
PT · 10731867 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€9,090 2024-05-08
Dupilumab 300 mg/2 ml Sol inj Caneta 2 ml SC
PT · 10709156 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€2,015,028 2024-04-22
VÁRIOS MEDICAMENTOS
PT · 10672962 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€14,952 2024-03-25
Medicamento Dupilumab Inj 300mg Caneta
PT · 11086953 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€335,838 2024-02-29
Medicamento Cemiplimab Inj 50mg/ml
PT · 11386849 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields +1
€132,446 2024-02-29
Medicamento Isatuximab Inj
PT · 11386659 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields +1
€63,999 2024-02-29
Ajuste direto para aquisição de vacina inactivada contra a poliomielite para suprir necessidades na área da saúde
PT · 10760057 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +2
€153,340 2024-02-28
VÁRIOS MEDICAMENTOS
PT · 10560881 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€252,544 2024-01-19
AD/1664/2023 - Dupilumab inj 300mg
PT · 10426391 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€67,167 2023-12-21
AD/1551/2023-Cemiplimab 350mg/7ml
PT · 10377004 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€7,358 2023-12-04
Next →
Overview
Total Value Won
€23,580,624,795
Contracts Won
7,813
Score 270380 · CRITICAL RISK
NIF
500134960
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.J. [P-80b1]
    Gerente
    since 2012-06-11
  • A.D. [P-b42a]
    Gerente
    since 2014-03-13
  • E.Y. [P-6b36]
    Gerente
    since 2009-07-20
  • E.Y. [P-6b36]
    Gerente
    since 2013-05-06
  • E.Y. [P-6b36]
    Gerente
    since 2017-04-21
  • F.H. [P-552f]
    Gerente
    since 2022-09-19
  • H.P. [P-8f90]
    Gerente
    since 2022-09-19
  • J.C. [P-68bf]
    Gerente
    since 2013-05-06
  • L.M. [P-2cbf]
    Gerente
    since 2017-04-21
  • M.A. [P-5a28]
    Gerente
    since 2012-03-29
  • P.H. [P-715b]
    Vogal
    since 2008-10-08
  • P.H. [P-715b]
    Gerente
    since 2009-07-20
  • P.H. [P-715b]
    Gerente
    since 2010-06-18
  • R.G. [P-82e4]
    Gerente
    since 2012-10-08
  • S.J. [P-ba88]
    Gerente
    since 2015-05-25
  • A.N. [P-619a]
    Sócio
    since 2009-07-20
  • A.N. [P-619a]
    Sócio
    since 2012-03-29
  • S.A. [P-d154]
    Sócio
    since 2012-03-29
  • S.A. [P-d154]
    Sócio
    since 2017-01-26
  • S.F. [P-48a6]
    Sócio
    since 2019-05-31
  • S.A. [P-7997]
    Sócio
    since 2012-03-29
  • S.A. [P-7997]
    Sócio
    since 2017-01-26
  • S.A. [P-7997]
    Sócio
    since 2019-05-31
  • S.A. [P-66a2]
    Sócio
    since 2009-07-20
  • S.A. [P-23ed]
    Sócio
    since 2009-07-20
  • S.A. [P-77cb]
    Sócio
    since 2009-07-20
  • A.J. [P-80b1]
    Gerente
    2013-05-06 → 2015-03-12
  • A.M. [P-e9b6]
    Gerente
    2017-04-21 → 2018-06-20
  • A.M. [P-3895]
    Administrador
    until 2008-07-24
  • C.J. [P-f846]
    Gerente
    2014-03-13 → 2014-10-14
  • F.A. [P-a314]
    Gerente
    2015-03-12 → 2015-05-25
  • F.J. [P-1a2d]
    Gerente
    2018-06-21 → 2022-09-19
  • F.H. [P-9178]
    Gerente
    2009-07-20 → 2010-07-12
  • J.R. [P-2e21]
    Gerente
    2010-06-18 → 2012-05-22
  • M.A. [P-5a28]
    Gerente
    2013-05-06 → 2013-12-12
  • M.A. [P-8a48]
    Gerente
    2017-04-21 → 2022-09-19
  • O.M. [P-f83e]
    Gerente
    2010-07-12 → 2012-10-08
  • R.G. [P-82e4]
    Gerente
    2013-05-06 → 2014-03-13
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned